FindTrial
Sign In

Application of trans-triiodothyronine (rT3) in constructing critical status score and outcome prognostic model

Application of trans-triiodothyronine (rT3) in constructing critical status score and outcome prognostic model

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500101340
Enrollment
Unknown
Registered
2025-04-23
Start date
2022-06-14
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Euthyroid sick syndrome

Interventions

Observation group:None

Sponsors

Xiangyang Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Stay in ICU for more than 24 hours; 2.Agree to participate in the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1.Have taken iodine-containing drugs (such as iodides, iodine-containing tablets, etc.), drugs that affect thyroid hormone levels (such as thyroid tablets, anti-thyroid drugs, etc.) within the past month 2.Pregnant and lactating women; 3.Patients who leave hospital or die because their family members give up treatment; 4.Patients with advanced malignant tumors or in non-resuscitable terminal state.

Design outcomes

Primary

MeasureTime frame
Thyroid function related indicators (FT3,TT3,FT4,TT4,TSH,rT3);Erythrocyte sedimentation rate, ESR;Acute physiology and chronic health evaluation II, APACHE II;Hospital death;Out-of-hospital death;—

Secondary

MeasureTime frame
C-reactive protein, CRP;Procalcitonin, PCT;B-type natriuretic peptides, BNP;—

Countries

China

Contacts

Public ContactShaoyong Xu

Xiangyang Central Hospital

yoji_xu@hotmail.com+86 186 2968 0357

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026